as on September 13, 2025 at 1:29 am IST
Day's Low
Day's High
1.18%
Downside
0.98%
Upside
52 Week's Low
52 Week's High
43.44%
Downside
2.44%
Upside
Check Ligand Pharmaceuticals Incorporated market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$3.2B
EPS (TTM)
6.9229
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
1.03%
PE Ratio (TTM)
45.89
Industry PE ratio
-3.8535542168674697
P/B Ratio
0PEG Ratio
1.5271
EBITDA
19.7M
Revenue (TTM)
187.6M
Profit Margin
-40.44%
Return On Equity TTM
491578800.00%
Track how Ligand Pharmaceuticals Incorporated P/E has moved over time to understand its valuation trends.
Ligand Pharmaceuticals Incorporated in the last 5 years
Lowest (9.67x)
December 31, 2023
Industry (-3.85x)
September 15, 2025
Today (45.89x)
September 15, 2025
Highest (30.05x)
September 30, 2020
Today’s Price to Earnings Ratio: 45.89x
Compare market cap, revenue, PE, and other key metrics of Ligand Pharmaceuticals Incorporated with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $3.2B | 72.67% | 45.89 | -40.44% | |
BUY | $61.1B | 256.98% | -505.15 | -12.96% | |
NA | $38.7B | NA | NA | -3.89% | |
BUY | $101.1B | 47.85% | 28.07 | 31.86% | |
BUY | $59.4B | -3.43% | 14.11 | 31.37% |
The Ligand Pharmaceuticals Incorporated stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Ligand Pharmaceuticals Incorporated investment value today
Current value as on today
₹1,63,056
Returns
₹63,056
(+63.06%)
Returns from Ligand Pharmaceuticals Incorporated Stock
₹57,917 (+57.92%)
Dollar Returns*
₹5,139 (+5.14%)
Based on 11 analysts
90.91%
Buy
9.09%
Hold
0.00%
Sell
Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Ligand Pharmaceuticals Incorporated. Average target price of $183.12
Get share price movements and forecasts by analysts on Ligand Pharmaceuticals Incorporated.
What analysts predicted
9.65%UPSIDE
Target Price
$183.12
Current Price
$165.45
Analyzed by
11 Analysts
Target
$183.12
Ligand Pharmaceuticals Incorporated target price $183.12, a slight upside of 9.65% compared to current price of $165.45. According to 11 analysts rating.
Search interest for Ligand Pharmaceuticals Incorporated Stock has increased by 80% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:80% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 2 quarters, -42.45M → 4.84M (in $), with an average increase of 975.8% per quarter
Revenue Rich
Revenue is up for the last 3 quarters, 42.81M → 47.62M (in $), with an average increase of 5.2% per quarter
Price Rise
In the last 3 months, LGND stock has moved up by 47.3%
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 123.5% return, outperforming this stock by 39.6%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 17.4%
Organisation | Ligand Pharmaceuticals Incorporated |
Headquarters | 555 Heritage Drive, Jupiter, FL, United States, 33458 |
Industry | Health Technology |
CEO | Mr. Todd C. Davis Ph.D. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Scott M. Plesha | CEO of Pelthos Therapeutics |
Mr. Andrew T. Reardon J.D. | Chief Legal Officer & Secretary |
Mr. Paul J. Hadden | Senior Vice President of Investments & Business Development |
Dr. Keith Marschke Ph.D. | Senior Vice President of Biology & Scientific Affairs |
Mr. Patrick Lucy | Senior VP & CBO Protein Expression Business |
Dr. Karen R. Reeves M.D. | Senior VP of Investments & Head of Clinical Strategy |
Mr. Todd C. Davis Ph.D. | CEO & Director |
Mr. Octavio Espinoza | Chief Financial Officer |
Dr. Vincent D. Antle Ph.D. | Senior Vice President of Technical Operations & QA - Capitsol |
Mr. Richard B. Baxter | Senior VP of Investment Operation |
Ligand Pharmaceuticals Incorporated share price today is $165.45 as on at the close of the market. Ligand Pharmaceuticals Incorporated share today touched a day high of $167.07 and a low of $163.5.
Ligand Pharmaceuticals Incorporated share touched a 52 week high of $169.49 on and a 52 week low of $93.58 on . Ligand Pharmaceuticals Incorporated stock price today i.e. is closed at $165.45,which is 2.38% down from its 52 week high and 76.80% up from its 52 week low.
Ligand Pharmaceuticals Incorporated market capitalisation is $0.00T as on .
Indian investors can start investing in Ligand Pharmaceuticals Incorporated (LGND) shares with as little as ₹88.27 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹882.70 in Ligand Pharmaceuticals Incorporated stock (as per the Rupee-Dollar exchange rate as on ).
Based on Ligand Pharmaceuticals Incorporated share’s latest price of $165.45 as on September 13, 2025 at 1:29 am IST, you will get 0.0604 shares of Ligand Pharmaceuticals Incorporated. Learn more about
fractional shares .
Ligand Pharmaceuticals Incorporated stock has given 72.67% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?